Kura Oncology, Inc. - 8-K Filing

Kura Oncology formed Caspian Therapeutics subsidiary and completed $50M Series A financing; transferred menin inhibitor assets for diabetes research (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $KURA

Read the full article at SEC EDGAR

More Regulatory news